Ricevi le ultime notizie sulle azioni Nuvectis Pharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NVCT

Ultime notizie per

Nuvectis Pharma

Nuvectis Pharma Inc

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Anika Therapeutics

Anixa Biosciences

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Cardiff Oncology

Elicio Therapeutics

Entera Bio

Forte Biosciences

Genfit

Heron Therapeutics

TuHURA Biosciences

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Spero Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Nuvectis Pharma (NVCT) Previsione

Quote.Nav.option-chain

Vendite allo scoperto

Rapporto azionario

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Comments

Nuvectis Pharma Notizie sulle azioni

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO